Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
Posted inClinical Updates Dermatology news

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients with moderate-to-severe hidradenitis suppurativa.
Bimekizumab Sustains Complete Skin Clearance and Quality of Life Improvements Through Three Years in Plaque Psoriasis: Insights from the BE RADIANT Trial
Posted inDermatology news

Bimekizumab Sustains Complete Skin Clearance and Quality of Life Improvements Through Three Years in Plaque Psoriasis: Insights from the BE RADIANT Trial

The BE RADIANT trial demonstrates that bimekizumab provides rapid, superior, and durable skin clearance (PASI 100) and symptom relief compared to secukinumab over three years, with a manageable safety profile and significant quality-of-life benefits for patients with moderate-to-severe plaque psoriasis.